According to the company, BIOMEnd contains L-Lysine Butyrate, the l-lysine salt of butyric acid, which is superior in form and completely soluble in liquid solution.
NutraShure Distribution LLC (East Setauket, NY) has announced the launch of BIOMEnd, a patent-pending form of the four-carbon short-chain fatty acid, butyrate, which is naturally-occurring in certain foods and produced during the fermentation of dietary fiber by gut bacteria. According to the company, BIOMEnd contains L-Lysine Butyrate, the l-lysine salt of butyric acid, which is superior in form and completely soluble in liquid solution.
NutraShure explains in a press release that through its role as a histone deacetylase, butyrate modulates responses of GI health. It’s also the primary energy source of colonocytes, which are the cells that line the colon and help maintain the integrity of the gut barrier, and can modulate immune function by influencing innate and adaptive immune responses.
“Addressing the palatability challenges associated with the commercially available butyrate and butyrate prodrugs currently on the market, the development of BIOMEnd represents a significant accomplishment for our team,” said Brandon Sojka, CEO of NutraShure and co-inventor of BIOMEnd, in a press release. “As a research scientist and a business owner, delivering a game-changing ingredient to the market is a career-long aspiration; which is now a reality.”
According to the company, in contract to butyrate supplements that have traditionally been on the market, BIOMEnd has consistent dispersion and distribution in liquid, eliminating concerns about taste, sedimentation, and uneven distribution.